Resource Logo

Coresistance to zidovudine and foscarnet is associated with multiple mutations in the human immunodeficiency virus type 1 reverse transcriptase.


Antimicrob Agents Chemother. 1998 Nov;42(11):3038-43. Unique Identifier

Human immunodeficiency virus type 1 (HIV-1) isolates obtained from a patient with AIDS were assessed for coresistance to foscarnet and zidovudine. An HIV-1 strain (AP20) coresistant to foscarnet and zidovudine was isolated after 20 months of continuous combination therapy. The reverse transcriptase (RT) gene of AP20 had 41 substitutions which were different from the HXB2-D sequence and 9 that were different from the sequence of its foscarnet-sensitive, zidovudine-resistant progenitor virus (AP6). Six of these mutations were nonpolymorphic (T39A, V108I, K166R, K219R, K223Q, and L228R). Both strains had the conventional mutations mediating zidovudine resistance. In vivo selection may result in HIV-1 strains that are coresistant to foscarnet and zidovudine, but coresistance appears to require a complex evolutionary path and multiple RT mutations.

JOURNAL ARTICLE Amino Acid Sequence Anti-HIV Agents/*PHARMACOLOGY Drug Resistance Foscarnet/*PHARMACOLOGY Human HIV-1/*DRUG EFFECTS HIV-1 Reverse Transcriptase/CHEMISTRY/*GENETICS Molecular Sequence Data *Mutation Polymerase Chain Reaction Support, Non-U.S. Gov't Zidovudine/*PHARMACOLOGY


Information in this article was accurate in February 28, 1999. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.